Combined radiotherapy and hormonal therapy in the treatment of prostate cancer.
The use of hormonal therapy as an adjunct to radiotherapy has been discussed controversially for years. Results of large RTOG and EORTC trials indicate that the combination of these treatment modalities may improve survival in subsets of patients. Many questions with respect to onset, duration, type of hormonal therapy and appropriate patient selection are still under investigation. Following a short overview of the corresponding literature, evidence-based recommendations for daily clinical practice are provided.
Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin , Germany.
Dirk
D
Boehmer
D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal